OBX · Obsidian Therapeutics, Inc.
Market Cap
$1.06B
Shares
61.77M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dana Alexander | Chief Technical Officer | Appointed | 2026-08-03 |
| Parameswaran Hari | Chief Medical Officer | Appointed | 2026-08-03 |
| Joel Sussman | Treasurer and Principal Financial and Accounting Officer | Resigned | 2026-08-03 |
| Julie Feder | Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer | Appointed | 2026-08-03 |
| J. Mel Sorensen | President and Principal Executive Officer | Resigned | 2026-08-03 |
| Madan Jagasia | Chief Executive Officer and principal executive officer | Appointed | 2026-08-03 |
| Maria Fardis, Ph.D., M.B.A. | Chairperson of the Board | Appointed | 2026-08-03 |
| Robert Ross, M.D. | Class III director | Appointed | 2026-08-03 |
| Maria Fardis, Ph.D., M.B.A. | Class III director | Appointed | 2026-08-03 |
| Heidi Hagen | Class II director | Appointed | 2026-08-03 |
| Madan Jagasia, M.D., M.S. | Class III director | Appointed | 2026-08-03 |
| Matthew Norkunas, M.D., M.B.A. | Class II director | Appointed | 2026-08-03 |
| Peter Barrett, Ph.D. | Class I director | Appointed | 2026-08-03 |
| Julie Feder | Board | Resigned | 2026-08-03 |
| J. Mel Sorensen, M.D. | Board | Resigned | 2026-08-03 |